Company registration number 11529802 (England and Wales)
CENTRE FOR HEALTH RESEARCH AND EDUCATION LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
PAGES FOR FILING WITH REGISTRAR
CENTRE FOR HEALTH RESEARCH AND EDUCATION LIMITED
COMPANY INFORMATION
Directors
Dr Pooja Patwardhan
Dr Sudhanshu Patwardhan
Company number
11529802
Registered office
C/O Xeinadin First Floor Secure House
Lulworth Close
Chandler's Ford
Eastleigh
Hampshire
England
SO53 3TL
Accountants
Xeinadin
12 Conqueror Court
Sittingbourne
Kent
United Kingdom
ME10 5BH
England
CENTRE FOR HEALTH RESEARCH AND EDUCATION LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
CENTRE FOR HEALTH RESEARCH AND EDUCATION LIMITED
BALANCE SHEET
AS AT
31 AUGUST 2025
31 August 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
40,965
52,410
Current assets
Debtors
5
14,397
19,716
Cash at bank and in hand
619,389
1,040,020
633,786
1,059,736
Creditors: amounts falling due within one year
6
(305,698)
(861,627)
Net current assets
328,088
198,109
Net assets
369,053
250,519
Capital and reserves
Called up share capital
1,100
1,100
Profit and loss reserves
367,953
249,419
Total equity
369,053
250,519

For the financial year ended 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with section 444 of the Companies Act 2006, all of the members of the company have consented to the preparation of abridged financial statements pursuant to paragraph 1A of Schedule 1 to the Small Companies and Groups (Accounts and Directors’ Report) Regulations (SI 2008/409)(b).

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 22 May 2026 and are signed on its behalf by:
Dr Pooja Patwardhan
Dr Sudhanshu Patwardhan
Director
Director
Company registration number 11529802 (England and Wales)
CENTRE FOR HEALTH RESEARCH AND EDUCATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
- 2 -
1
Accounting policies
Company information

Centre For Health Research And Education Limited is a private company limited by shares incorporated in England and Wales. The registered office is C/O Xeinadin First Floor Secure House, Lulworth Close, Chandler's Ford, Eastleigh, Hampshire, England, SO53 3TL.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recover able.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
5 years Straight line
Office Equipment
4 years Straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

CENTRE FOR HEALTH RESEARCH AND EDUCATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 3 -
1.5
Foreign exchange

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
2
1
3
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
75,373
139,844
Adjustments in respect of prior periods
(223,115)
(70)
Total current tax
(147,742)
139,774

A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period

4
Tangible fixed assets
Total
£
Cost
At 1 September 2024
86,621
Additions
5,246
At 31 August 2025
91,867
Depreciation and impairment
At 1 September 2024
34,211
Depreciation charged in the year
16,691
At 31 August 2025
50,902
Carrying amount
At 31 August 2025
40,965
At 31 August 2024
52,410
CENTRE FOR HEALTH RESEARCH AND EDUCATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 4 -
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
13,068
2,235
Other debtors
1,329
17,481
14,397
19,716

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

6
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans and overdrafts
276
425
Trade creditors
1,320
1,967
Taxation and social security
(135,996)
57,784
Other creditors
440,098
801,451
305,698
861,627

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

2025-08-31 2024-09-01 false false false 22 May 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Dr Pooja Patwardhan Dr Sudhanshu Patwardhan 11529802 2024-09-01 2025-08-31 11529802 bus:Director1 2024-09-01 2025-08-31 11529802 bus:Director2 2024-09-01 2025-08-31 11529802 bus:RegisteredOffice 2024-09-01 2025-08-31 11529802 2025-08-31 11529802 2024-08-31 11529802 core:CurrentFinancialInstruments core:WithinOneYear 2025-08-31 11529802 core:CurrentFinancialInstruments core:WithinOneYear 2024-08-31 11529802 core:WithinOneYear 2025-08-31 11529802 core:WithinOneYear 2024-08-31 11529802 core:CurrentFinancialInstruments 2025-08-31 11529802 core:CurrentFinancialInstruments 2024-08-31 11529802 core:ShareCapital 2025-08-31 11529802 core:ShareCapital 2024-08-31 11529802 core:RetainedEarningsAccumulatedLosses 2025-08-31 11529802 core:RetainedEarningsAccumulatedLosses 2024-08-31 11529802 core:FurnitureFittings 2024-09-01 2025-08-31 11529802 core:ComputerEquipment 2024-09-01 2025-08-31 11529802 2023-09-01 2024-08-31 11529802 core:UKTax 2024-09-01 2025-08-31 11529802 core:UKTax 2023-09-01 2024-08-31 11529802 2024-08-31 11529802 bus:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 11529802 bus:SmallCompaniesRegimeForAccounts 2024-09-01 2025-08-31 11529802 bus:FRS102 2024-09-01 2025-08-31 11529802 bus:AuditExemptWithAccountantsReport 2024-09-01 2025-08-31 11529802 bus:FullAccounts 2024-09-01 2025-08-31 xbrli:pure xbrli:shares iso4217:GBP